Aclarion Appoints Daniel Keefe as Commercial Director to Drive Nociscan Adoption in Western U.S.

Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and augmented intelligence (AI) to help physicians identify the source of chronic low back pain, today announced the appointment of Daniel Keefe as Commercial Director, Western U.S. Keefe will lead commercial efforts across the Western region, building on Aclarion’s existing footprint and supporting continued adoption of Nociscan, the company’s cloud-based diagnostic platform.

The appointment comes as Aclarion reports triple-digit growth in Nociscan utilization, with increasing engagement across academic institutions and high-volume private practice spine centers. The company has established a growing presence in the Western U.S., and Keefe’s role reflects a strategic focus on deepening adoption in a key region. “Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies,” said Brent Ness, Chief Executive Officer of Aclarion. “His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S.”

Keefe joins Aclarion with more than 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, as Regional Sales Manager at Centinel Spine, he consistently exceeded performance targets and delivered significant year-over-year growth across the Northern California region. Throughout his career, Keefe has demonstrated success in building strategic relationships with surgeons and hospital leadership, launching new technologies, and expanding market presence in competitive environments.

“I’m excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community,” said Daniel Keefe, Commercial Director, Western U.S. “The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice.”

Chronic low back pain affects an estimated 266 million people worldwide, making it one of the most pervasive health challenges. Aclarion’s Nociscan solution is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. To find a Nociscan center, view the company’s site map here.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. Through a cloud connection, Nociscan receives MRS data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers, which are entered into proprietary algorithms to indicate if a disc may be a source of pain. For more information, visit www.aclarion.com.